Gene Synthesis Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Gene synthesis is the laboratory-based manufacturing of custom DNA sequences, ranging from short oligos to entire genes and plasmids, serving as a foundational technology for biotech, pharmaceutical, and academic research. The global market in 2025 is valued at approximately USD 2.57 billion, with projections suggesting it could reach between USD 10.3 billion and nearly USD 33 billion by the early 2030s depending on the forecast model. Market sizing is tracked entirely by private-sector commercial research firms, as no government statistical agency, including the NIH or WHO, publishes a direct market valuation for this industry.

• •No government statistical agency publishes an official or definitive market size figure for gene synthesis
• •Estimated 2025 market values across sources range from roughly USD 1.1 billion to USD 3.42 billion
• •The market is broadly defined to include gene synthesis services, oligo synthesis, and synthetic biology platforms

The principal forces propelling market expansion include declining costs of DNA sequencing and synthesis, the rapid growth of biologics pipelines in the pharmaceutical industry, and rising investment in synthetic biology. The expansion of mRNA-based vaccine and therapeutic programs, the proliferation of CRISPR-based gene editing research, and increasing demand from academic and government research institutions are further accelerating adoption. Supportive government funding for genomics programs and biotechnology innovation also underpins steady demand from public-sector research end-users.

• •Falling DNA synthesis and sequencing costs have made custom gene construction increasingly cost-effective
• •Growth in biologics pipelines, cell therapies, and mRNA therapeutics is driving commercial demand
• •Academic and government research institutes remain one of the largest end-user segments

The market is typically segmented by product type, oligo synthesis, gene-length synthesis, and plasmid construction, as well as by end-user, including pharmaceutical and biotech companies, academic and government research institutions, and contract research organizations. Geographically, North America holds the largest share of the global market, supported by a dense concentration of biopharmaceutical R&D activity and significant government research funding. Europe ranks second, while the Asia-Pacific region, particularly China, Japan, and India, is emerging as the fastest-growing area, fueled by rising biotech infrastructure and outsourcing activity.

• •North America is the dominant regional market, followed by Europe, with Asia-Pacific the fastest-growing region
• •Pharmaceutical and biotechnology companies represent the largest commercial end-user segment
• •Academic and government research institutions are a major and consistently growing end-user category

What are the recent trends and outlook?

Several emerging trends are expected to shape the gene synthesis market over the coming decade, including the integration of artificial intelligence for de novo gene and protein design, the development of biofoundries for automated large-scale DNA assembly, and rising demand for cell-free synthesis platforms. Regulatory scrutiny and bio-safety concerns, particularly around the synthesis of potentially harmful sequences, may introduce new compliance frameworks that influence industry operations. Despite these challenges, the combination of maturing synthetic biology capabilities, expanding therapeutic pipelines, and continued cost reductions positions the market for robust long-term growth.

• •AI-driven de novo design and biofoundry automation are accelerating the speed and scale of synthetic gene production
• •Cell-free gene expression and synthesis technologies are gaining traction for rapid prototyping
• •Ongoing bio-safety and dual-use research governance frameworks may increasingly shape the regulatory environment